{
    "2021-08-31": [
        [
            {
                "time": "",
                "original_text": "中泰证券维持康泰生物买入评级：业绩基本符合预期，期待PCV13+HDCV",
                "features": {
                    "keywords": [
                        "康泰生物",
                        "买入评级",
                        "业绩",
                        "PCV13",
                        "HDCV"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "康泰生物(300601)：核心产品恢复放量 13价肺炎疫苗兑现再即",
                "features": {
                    "keywords": [
                        "康泰生物",
                        "核心产品",
                        "放量",
                        "13价肺炎疫苗"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "康泰生物(300601)：业绩略超预期 关注新冠放量及PCV13获批进展",
                "features": {
                    "keywords": [
                        "康泰生物",
                        "业绩",
                        "新冠",
                        "PCV13",
                        "获批"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "康泰生物(300601)2021年中报点评：灭活新冠疫苗有望带来业绩增量 PCV13+二倍体狂苗值得期待",
                "features": {
                    "keywords": [
                        "康泰生物",
                        "灭活新冠疫苗",
                        "业绩增量",
                        "PCV13",
                        "二倍体狂苗"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "康泰生物(300601)：业绩符合预期 新冠疫苗贡献增量",
                "features": {
                    "keywords": [
                        "康泰生物",
                        "业绩",
                        "新冠疫苗",
                        "增量"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}